Omeros Announces Promising Data from Phase 1 OMS824 Clinical Trial
December 06, 2012 at 07:13 AM EST
Omeros Corporation (NASDAQ: OMER ) today announced promising data from the single-ascending-dose (SAD) study portion of the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide
